Not currently recruiting at UCSF
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Elliot Vichinsky, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Elliot Vichinsky, MD
I am the Director of Hematology/Oncology at UCSF Benioff Children's Hospital Oakland, Adjunct Professor at University of California San Francisco, as well as the Director of the Northern California Sickle Cell and Thalassemia Centers. I am a board-certified pediatric hematologist/oncologist with a major interest in understanding and improving the care of patients with hemoglobinopathies.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Global Blood Therapeutics
- Links
- Global Blood Therapeutics (GBT) website
- ID
- NCT04935879
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 240 study participants
- Last Updated